- Home
- NERV vs NXTT Comparison
NERV vs NXTT Comparison
Compare NERV & NXTT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- NXTT
- Stock Information
- Founded
- NERV 2007
- NXTT 2019
- Country
- NERV United States
- NXTT China
- Employees
- NERV N/A
- NXTT N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- NXTT
- Sector
- NERV Health Care
- NXTT
- Exchange
- NERV Nasdaq
- NXTT NYSE
- Market Cap
- NERV 16.0M
- NXTT 16.8M
- IPO Year
- NERV 2014
- NXTT N/A
- Fundamental
- Price
- NERV $2.23
- NXTT $2.82
- Analyst Decision
- NERV Hold
- NXTT
- Analyst Count
- NERV 1
- NXTT 0
- Target Price
- NERV $5.00
- NXTT N/A
- AVG Volume (30 Days)
- NERV 37.0K
- NXTT 55.0K
- Earning Date
- NERV 02-20-2025
- NXTT 11-15-2024
- Dividend Yield
- NERV N/A
- NXTT N/A
- EPS Growth
- NERV N/A
- NXTT N/A
- EPS
- NERV N/A
- NXTT 3.59
- Revenue
- NERV N/A
- NXTT $1,133,308.00
- Revenue This Year
- NERV N/A
- NXTT N/A
- Revenue Next Year
- NERV N/A
- NXTT N/A
- P/E Ratio
- NERV N/A
- NXTT $0.80
- Revenue Growth
- NERV N/A
- NXTT N/A
- 52 Week Low
- NERV $2.06
- NXTT $0.94
- 52 Week High
- NERV $13.49
- NXTT $6.66
- Technical
- Relative Strength Index (RSI)
- NERV 50.40
- NXTT 58.28
- Support Level
- NERV $2.07
- NXTT $2.27
- Resistance Level
- NERV $2.39
- NXTT $2.80
- Average True Range (ATR)
- NERV 0.12
- NXTT 0.39
- MACD
- NERV -0.01
- NXTT -0.03
- Stochastic Oscillator
- NERV 48.48
- NXTT 54.69
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About NXTT NEXT TECHNOLOGY HOLDING INC
Next Technology Holding Inc pursues two corporate strategies. One business strategy is to continue providing software development services, and the other strategy is to acquire and hold Bitcoin. It provides AI-enabled software development services to its customers, which include developing, designing, and implementing various SAAS software solutions for businesses of all types, including industrial and other businesses. Its bitcoin acquisition strategy generally involves acquiring bitcoin with its liquid assets that exceed working capital requirements, and from time to time, subject to market conditions, issuing debt or equity securities or engaging in other capital raising transactions to use the proceeds to purchase bitcoin.